1 study found for:    NCI-2010-01738
Show Display Options
Rank Status Study
1 Active, not recruiting Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Conditions: Recurrent Uterine Corpus Sarcoma;   Stage IIIA Uterine Sarcoma;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Other: Placebo;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Drug: Docetaxel;   Biological: Filgrastim;   Biological: Pegfilgrastim

Indicates status has not been verified in more than two years